


each R is independently a hydrogen, -CF<sub>3</sub>, -CF<sub>2</sub>H, -CFH<sub>2</sub>, -CH<sub>2</sub>CF<sub>3</sub>, phenyl or C<sub>1</sub>-C<sub>10</sub> linear, branched, cyclic, fused cyclic and/or bicyclic alkyl having sp, sp<sup>2</sup> and/or sp<sup>3</sup> hybridization; each X is independently a hydrogen, fluoro, chloro, bromo, iodo, -OR, -N(R)<sub>2</sub>, -SR, -S(O)R, -S(O)<sub>2</sub>R, cyano, nitro, -C(O)R, -OC(O)R, -C(O)OR, -N(R)-C(O)R or -C(O)NR<sub>2</sub>; and each m is independently 0, 1, 2, 2, 4, 5, 6, or 7.

81. (Amended) The compound of claim 77 having the formula



or a pharmaceutically acceptable salt or complex thereof, wherein Y<sup>1</sup> and Y<sup>2</sup> are each independently an aromatic or cycloaliphatic ring or ring system; and

R<sub>1</sub> and R<sub>2</sub> are each independently a hydrogen, -CF<sub>3</sub>, -CF<sub>2</sub>H, -CFH<sub>2</sub>, -CH<sub>2</sub>CF<sub>3</sub>, phenyl or C<sub>1</sub>-C<sub>10</sub> linear, branched, cyclic, fused cyclic, and/or bicyclic alkyl having sp, sp<sup>2</sup> and/or sp<sup>3</sup> hybridization.

## REMARKS

### 1. Priority Claim

The Examiner states that no specific reference has been made of earlier filed application Serial No. 08/484,159. But the filing papers filed with the application contain instructions at page 3 to amend the specification to recite a reference to application 08/484,159, filed June 7, 1995. Therefore it is believed all conditions for receiving the benefit of the earlier filing date have been complied with.